Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 929

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 929
---
 par value; 58,251,629 shares authorized as ofSeptember 30, 2024 and December 31, 2023; 19,197,914 and 19,134,164shares issued and outstanding as of September 30, 2024 and December 31,2023, respectively                                                                                                           | ​ | ​ | ​                      | ​ |      19 | ​ | ​ | ​ | ​                     | ​ |      19 | ​ | ​ |
| Additional paid-in capital                                                                                                                                                                                                                                                                                                               | ​ | ​ | ​                      | ​ |   1,007 | ​ | ​ | ​ | ​                     | ​ |     762 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                                                                                      | ​ | ​ | ​                      | ​ | -79,529 | ​ | ​ | ​ | ​                     | ​ | -62,839 | ​ | ​ |
| Total stockholders’ deficit                                                                                                                                                                                                                                                                                                              | ​ | ​ | ​                      | ​ | -78,503 | ​ | ​ | ​ | ​                     | ​ | -62,058 | ​ | ​ |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit                                                                                                                                                                                                                                                     | ​ | ​ | ​                      | $ |  12,514 | ​ | ​ | ​ | ​                     | $ |  27,001 | ​ | ​ |

The accompanying notes are an integral part of these unaudited condensed financial statements. F-115

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. CONDENSED Statements of Operations
(Amounts in thousands, except share and per share amounts)
(Unaudited)

| ​                                                                         
 ​                                                                         
 Operating expenses:                                                       | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Nine Months EndedSeptember 30, 
 2024                                   
 ​                                      | ​ |          ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2023 
 ​    | ​ |          ​ | ​ | ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------|:--|:--|:---------------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Research and development                                                  | ​ | ​ | ​                                      | $ |     15,047 | ​ | ​ | ​ | ​    | $ |     11,884 | ​ | ​ |
| General and administrative                                                | ​